BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 9312811)

  • 1. [Renal cell carcinoma--a current review].
    Schmid HP; Szabo J
    Praxis (Bern 1994); 1997 May; 86(20):837-43. PubMed ID: 9312811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes.
    Parekh DJ; Cookson MS; Chapman W; Harrell F; Wells N; Chang SS; Smith JA
    J Urol; 2005 Jun; 173(6):1897-902. PubMed ID: 15879771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
    Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
    J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal cell carcinoma: presentation, staging, and surgical treatment.
    Russo P
    Semin Oncol; 2000 Apr; 27(2):160-76. PubMed ID: 10768595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.
    Hofmann HS; Neef H; Krohe K; Andreev P; Silber RE
    Eur Urol; 2005 Jul; 48(1):77-81; discussion 81-2. PubMed ID: 15967255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A clinical study of renal tumors].
    Tamai H; Ogawa T; Mitsui H; Nagakubo I
    Hinyokika Kiyo; 1983 Oct; 29(10):1255-68. PubMed ID: 6681500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
    Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
    J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal angiosarcoma: a case report and literature review.
    Lee TY; Lawen J; Gupta R
    Can J Urol; 2007 Feb; 14(1):3471-6. PubMed ID: 17324331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adenocarcinoma of the kidney (hypernephroma)].
    Probst W; Joss R; Triller J; Schönenberger A; Greiner R; Brunner KW
    Schweiz Med Wochenschr; 1984 Oct; 114(41):1406-15. PubMed ID: 6208605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
    Itano NB; Blute ML; Spotts B; Zincke H
    J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes following partial nephrectomy by tumor size.
    Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
    J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous radiofrequency ablation with transarterial embolization is useful for treatment of stage 1 renal cell carcinoma with surgical risk: results at 2-year mean follow up.
    Arima K; Yamakado K; Kinbara H; Nakatsuka A; Takeda K; Sugimura Y
    Int J Urol; 2007 Jul; 14(7):585-90; discussion 590. PubMed ID: 17645597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real indications for adrenalectomy in renal cell carcinoma.
    Moudouni SM; En-Nia I; Patard JJ; Manunta A; Guillé F; Lobel B
    Scand J Urol Nephrol; 2002; 36(4):273-7. PubMed ID: 12201919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
    Yoo C; Song C; Hong JH; Kim CS; Ahn H
    J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma.
    Levy DA; Slaton JW; Swanson DA; Dinney CP
    J Urol; 1998 Apr; 159(4):1163-7. PubMed ID: 9507823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.